Tagged with ipha

Morocco Morocco is undergoing ambitious reforms, extending universal healthcare coverage to all its citizens while resolving the shortcomings laid bare during the COVID-19 pandemic. Endorsed by a USD 450 million Program-for-Results loan from the World Bank, the government’s plans have been well received by the country’s healthcare and life sciences stakeholders…

Morocco The COVID-19 pandemic exposed Africa’s dependence on overseas production as vaccines were quickly rolled out in other parts of the world while  African countries remained at the bottom of the list. The need to build capacity on the continent has been widely recognized, but few Western actors have yet made…

Morocco MARBIO, a new vaccine manufacturing joint venture in Morocco, is the result of a partnership between the BAB banking consortium (Bank of Africa, Banque Centrale Populaire, and Attijariwafa Bank), Swedish CDMO Recipharm and the Mohammed VI Fund. Recipharm CEO Marc Funk and MARBIO General Manager Younès Hillali outline the scale…

Belgium Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly, pharmacists have emerged as crucial members of the healthcare team, playing integral roles in patient care, medication management, and promoting…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

Morocco After implementing the most successful COVID-19 inoculation campaign on the African continent, Morocco is looking to bolster its biologics and vaccine manufacturing capacity via two major agreements with Swedish CDMO Recipharm and Chinese Sinopharm. The North African nation hopes to be better able to supply the health needs of its…

Switzerland Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in the largely unexplored rare diseases generics space, its direct presence in the German market, and the opportunities inherent in metabolic…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…

UAE From Turkey to Tajikistan, Bangladesh to Bahrain, and Russia to Rwanda, multinational pharma firms are increasingly situating wide-ranging management responsibilities in the UAE. The following is an inexhaustive list of some of the widely varying geographies being managed from the UAE, as well as insights from the executives overseeing them.…

UAE Mundipharma, through its model of independent associated companies, is aiming to take the lead in the Middle East, Turkey & Africa markets through its continuous commitment to improving peoples’ lives. Ashraf Allam, regional VP for the META region, discusses his journey of building Mundipharma’s strong footprint in the region and…

Sweden Since going public five years ago, Recipharm, Sweden’s iconic indigenous contract development and manufacturing organization (CDMO), has seen its sales skyrocket by over 30 percent annually. Much of this growth has been driven by an acquisition streak with the company plucking up overseas production assets such as former Roche and…